Abstract
Objectives
To assess 3-Tesla (3-T) ultra-small superparamagnetic iron oxide (USPIO)-enhanced MRI in detecting lymph node (LN) metastases for resectable adenocarcinomas of the pancreas, duodenum, or periampullary region in a node-to-node validation against histopathology.
Methods
Twenty-seven consecutive patients with a resectable pancreatic, duodenal, or periampullary adenocarcinoma were enrolled in this prospective single expert centre study. Ferumoxtran-10-enhanced 3-T MRI was performed pre-surgery. LNs found on MRI were scored for suspicion of metastasis by two expert radiologists using a dedicated scoring system. Node-to-node matching from in vivo MRI to histopathology was performed using a post-operative ex vivo 7-T MRI of the resection specimen. Sensitivity and specificity were calculated using crosstabs.
Results
Eighteen out of 27 patients (median age 65 years, 11 men) were included in the final analysis (pre-surgery withdrawal n = 4, not resected because of unexpected metastases peroperatively n = 2, and excluded because of inadequate contrast-agent uptake n = 3). On MRI 453 LNs with a median size of 4.0 mm were detected, of which 58 (13%) were classified as suspicious. At histopathology 385 LNs with a median size of 5.0 mm were found, of which 45 (12%) were metastatic. For 55 LNs node-to-node matching was possible. Analysis of these 55 matched LNs, resulted in a sensitivity and specificity of 83% (95% CI: 36–100%) and 92% (95% CI: 80–98%), respectively.
Conclusion
USPIO-enhanced MRI is a promising technique to preoperatively detect and localise LN metastases in patients with pancreatic, duodenal, or periampullary adenocarcinoma.
Clinical relevance statement
Detection of (distant) LN metastases with USPIO-enhanced MRI could be used to determine a personalised treatment strategy that could involve neoadjuvant or palliative chemotherapy, guided resection of distant LNs, or targeted radiotherapy.
Registration
The study was registered on clinicaltrials.gov NCT04311047. https://clinicaltrials.gov/ct2/show/NCT04311047?term=lymph+node&cond=Pancreatic+Cancer&cntry=NL&draw=2&rank=1.
Key Points
-
LN metastases of pancreatic, duodenal, or periampullary adenocarcinoma cannot be reliably detected with current imaging.
-
This technique detected LN metastases with a sensitivity and specificity of 83% and 92%, respectively.
-
MRI with ferumoxtran-10 is a promising technique to improve preoperative staging in these cancers.
Explore related subjects
Find the latest articles, discoveries, and news in related topics.Avoid common mistakes on your manuscript.
Introduction
Lymph node (LN) metastases are associated with decreased overall survival (OS) for pancreatic ductal adenocarcinoma (PDAC, 11% vs 4% 5-year OS), duodenal, and periampullary tumours (cholangiocarcinoma 47% vs 24% 5-year OS, duodenal cancer 65% vs 21% 5-year OS, and ampulla of Vater cancer 61 vs 25 months median survival) [1,2,3,4]. Especially para-aortic LN metastases, classified as distant metastases by the TNM criteria of the Union for International Cancer Control (UICC, [5]), are associated with lower survival [6, 7]. Therefore, adequate LN assessment is critical in managing these cancers.
Conventional diagnostic imaging for pancreatic, duodenal, and periampullary cancer, including contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MRI), fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography ([18F]FDG-PET-CT), and endoscopic ultrasound (EUS), demonstrate limited sensitivity and specificity for detecting LN metastases. CECT for pre-operative assessment of extra-regional LN metastases in pancreatic, duodenal, and periampullary cancer has a sensitivity of 25–29% and a specificity of 83–86% [8, 9]. A study focusing on para-aortic LN metastases in pancreatic cancer with CECT, MRI, and [18F]FDG-PET-CT failed to identify any metastatic nodes, resulting in a sensitivity of 0% for all modalities [10]. Although only six patients in this study had histologically proven para-aortic LN metastases, this underscores the challenges in the accurate detection of metastases in this region. Additionally, a study involving 490 patients with resected PDAC found no significant difference in the percentage of LN metastases at histopathology between patients with or without enlarged LNs on preoperative imaging (CT, MRI, or EUS) [11]. This study concluded that size, commonly relied upon for LN metastase detection, is unreliable in predicting malignant LNs.
Ferumoxtran-10, an ultra-small superparamagnetic iron oxide (USPIO) particle, is a potentially valuable MRI contrast agent for detecting LN metastases [12, 13]. After intravenous administration, macrophages take up these particles and accumulate in non-metastatic, i.e. healthy (parts of) LNs. The paramagnetic properties of the iron core locally disturb the homogeneity of the MR system’s main magnetic field. Therefore, healthy LNs, with accumulated USPIO particles, exhibit a reduced signal intensity on T2*-weighted sequences. Conversely, in LN areas with metastases, the absence of USPIO particles results in a (partly) high signal intensity on T2*-weighted sequences [14]. A meta-analysis from 2011 combining different cancer types showed a mean sensitivity of 90% and a specificity of 96% of USPIO-enhanced MRI in detecting malignant LNs [15]. However, no studies with pancreatic, duodenal, or periampullary adenocarcinoma were included and results from tumours with a different entity, anatomical location, and vascularisation cannot simply be extrapolated.
We hypothesise that USPIO-enhanced MRI can accurately detect LN metastases for pancreatic, duodenal, and periampullary tumours. Accurate identification of LN metastases could tailor treatment plans including palliative or neoadjuvant chemotherapy, targeted resection of distant LNs, or targeted radiotherapy. This study aims to assess 3-T USPIO-enhanced MRI in detecting LN metastases for resectable adenocarcinomas of the pancreas, duodenum, or periampullary region, in a node-to-node validation against histopathology.
Materials and methods
The institutional review board approved this prospective single-centre cohort study and written informed consent was obtained. The study was registered on clinicaltrials.gov (NCT04311047) and conducted in accordance with the Declaration of Helsinki and the Dutch Medical Research Involving Human Subjects Act. Treatment-naïve patients with pancreatic, duodenal, or periampullary adenocarcinoma scheduled for surgical resection at the Radboudumc (tertiary hepatobiliary centre) between May 2017 and December 2020 were consecutively included. Eligibility was determined at the multidisciplinary pancreaticobiliary cancer meeting. The periampullary region was defined as the distal common bile duct, ampulla of Vater, and 2 cm of the duodenum surrounding the ampulla. Exclusion criteria were neoadjuvant treatment, distant metastases on preoperative imaging, other concomitant malignancies (prior malignancies: at least 5 years disease-free), or contraindications for MRI or USPIO (allergy, hemochromatosis, thalassemia, or sickle cell anaemia).
Procedures
Preoperative USPIO-enhanced MRI was conducted using ferumoxtran-10 (Ferrotran, SPL Medical B.V., investigational product), administered intravenously (2.6 mg/kg body weight) 24–36 h before the scan, as previously described [16]. MRI was performed on a 3-T MRI system (Magnetom Prisma, Siemens Healthcare). Butylscopolamine and glucagon were administered to minimise peristaltic motion, unless contraindicated. Patients were positioned feet first supine, with body phased array coils around the upper abdomen. The scan range was from diaphragm to aortic bifurcation. Images were acquired with repeated breath-holds of maximally 20 s on expiration. MRI sequences included T2-weighted HASTE for anatomical reference, T1-weighted VIBE DIXON for LN localisation, and fat-suppressed T2*-weighted multi gradient echo (mGRE) sequence for USPIO visualisation, mGRE images were reconstructed to a single T2*-weighted computed echo time (TE) of 12 ms [17]. Table 1 describes the technical details of the MR sequences.
Image evaluation
A radiologist (A.N., 18 years experience in abdominal imaging) analysed all USPIO-enhanced MRI images. A second radiologist (J.H., 23 years experience in pancreatic imaging) supervised the analysis. Disagreements were resolved in a consensus meeting. Both radiologists were blinded to the histopathology results. All visible LNs, regional and distant, were annotated and measured (short axis on axial orientation). LN locations were indicated using the classification of the Japan Pancreas Society [18]. LNs were scored on the iron-sensitive T2*-weighted mGRE (TE = 12 ms) sequence, using diagnostic guidelines adapted from Anzai et al (Table 2, [19]). Type 1–4 LNs were classified as suspicious for metastases and type 5–7 LNs as non-suspicious. The distinction between regional and distant LNs was based on the TNM classification (eighth edition) by the UICC [5]. The definition of regional nodes differs depending on the cancer type (pancreatic head or tail, cholangial, ampullary, or duodenal), the respective definition for each tumour type was applied.
Surgical resection and specimen analysis
Operative procedures, performed by experienced surgeons in pairs (mean experience nine years), contained pylorus resecting pancreatoduodenectomy (PRPD) with lymphadenectomy (stations no. 5, 6, 8a, 12b1/2, 12c, 13a/b, 14a/b, and 17a/b) or distal pancreatectomy (DP) with lymphadenectomy (station no. 10, 11, and 18) as indicated by the International Study Group on Pancreatic Surgery (ISGPS) [20]. Additional para-aortic or other distant LNs were resected if indicated as suspicious on MRI and resection was technically possible and safe. Resection specimens were pinned on an anatomical drawing for orientation.
A high-resolution ex vivo MRI of the fresh resection specimen and separately resected LNs was performed on a 7-T preclinical MRI system (Clinscan, Bruker® BioSpin). Ex vivo images had a resolution of 0.29 × 0.29 × 0.29 mm3 and consisted of a water and lipid-excited T1-weighted image according to a predefined workflow [16]. Subsequently, the tumour was fixated in formaldehyde for at least 48 h and then sliced into 4-mm slices following the axial slicing technique [21]. LNs from the peripancreatic fat were removed and enclosed separately, LNs larger than 5 mm were sectioned in 2–3 mm thick sections for paraffin embedding. Coupes were 4 µm with haematoxylin and eosin (H&E) staining. In contrast to measurement on MRI (short axis on axial orientation), at pathology, the largest diameter of the LNs was measured, as is clinical routine.
Node-to-node evaluation
Aided by the ex vivo MRI, LNs from in vivo MRI were matched to pathology for node-to-node analysis. Clinical follow-up imaging was used to confirm if an LN was indeed resected or not. Matching criteria were size, shape, and location, including anatomical landmarks such as surrounding vessels and organs. Only matched LNs were included in the validation analysis. A pancreas pathologist (L.B., ten years of expertise) re-evaluated all matched LNs.
Statistical analysis was performed using SPSS (version 25). The sensitivity and specificity of USPIO-MRI were calculated with crosstabs, using pathology as the reference standard. Continuous variables were summarised using standard descriptive statistics (mean, standard deviation, median, and range), and categorical variables were summarised with frequencies.
Re-evaluation
After prospective analysis, a third radiologist (P.Z., eight years experience with USPIO-enhanced MRI) reviewed all false positive and false negative LNs to investigate potential reasons for misclassification.
Results
Twenty-seven treatment-naïve patients scheduled for resection were enrolled in this prospective study. Figure 1 shows the patient flow. Four patients were excluded before surgery, and two patients were excluded because they were not resected due to unexpected metastases found intraoperatively. In three patients all LNs, both supra- and infra-diaphragmatic, had a high signal intensity on T2*-weighted images, suggesting inadequate uptake or distribution of ferumoxtran-10. Patient characteristics (age, tumour type, medical history, BMI, smoking, and alcohol), laboratory results (bilirubin, renal function, haemoglobin, and leucocytes), MRI analysis (no other abnormalities were seen), and histopathological investigation (both metastatic and normal benign LNs were present in each patient at histopathology), did not show a possible cause for non-uptake of ferumoxtran-10. We excluded these three patients from further analysis. Eighteen patients (11 male, seven female; median age 65) were included in the final analysis (characteristics in Table 3). Supplementary Fig. S1 and S2 show the distribution of regional and distant LNs and size distribution. The time between MRI and surgery was seven days median (range 1–26). At least one follow-up CT was performed in 13 patients (72%), the first CT was after 3 months median (range 1–13).
Safety
Ferumoxtran-10 administration and MRI were performed according to protocol in 23 patients, without any adverse events. Additional para-aortic LNs were resected for study purposes in 11 patients. Postoperative chyle leak occurred in three patients of which only one had undergone additional para-aortic LN resection.
LN scoring USPIO-enhanced MRI
In the 18 patients included in the final analysis, 453 LNs in total were detected on the USPIO-enhanced MRI. Their median size was 4.0 mm (range 2–20 mm) and there was a median of 23 LNs per patient (range 5–45). The majority of LNs were distant (n = 343). Assessment of the second radiologist and consensus meeting resulted in eight additionally identified LNs, four classified as not being LNs, ten LNs with a change in score without a change in suspicion, and ten LNs with a change in score that also resulted in a change of suspicion (four from non-suspicious to suspicious and six from suspicious to non-suspicious).
Fifty-eight LNs (13%) were scored as suspicious (type 1–4) on mGRE (TE = 12 ms), 394 LNs (87%) as non-suspicious (type 5–7), and one LN was not evaluable. The number of LNs for each type is shown in Table 4. Twenty-seven LNs (6%) were 10 mm or larger on MRI, of which 11 (41%) were scored as suspicious. Most suspicious LNs were para-aortic for all tumour types, except duodenal adenocarcinoma (zero suspicious para-aortic LNs).
Histopathology
At histopathology, 385 LNs in total were found, the median size was 5.0 mm (range 1–27 mm) and there was a median number of 19 LNs per patient (range 11–48). The majority of LNs were regional (n = 346). Forty-five LNs (11.7%) were metastatic, of which 41 were regional, and four were distant (resulting in M1 classification in patient nr. 2, 8, and 12). Seventy-five LNs (19%) were 10 mm or larger, of which 15 (20%) were metastatic.
Node-to-node correlation
Node-to-node matching from USPIO-MRI to histopathology was possible for 55 LNs from the 18 included patients. Six of these LNs were metastatic and 49 benign. Median size was 5.0 mm on MRI (range 2–14 mm) and 10.0 mm at histopathology (range 3–27 mm). Most matched LNs were regional LNs (n = 46). There were five (9%) true positives, 45 (82%) true negatives, four (7%) false positives, and one (2%) false negatives on mGRE TE = 12 ms. Sensitivity and specificity on a node-to-node basis for mGRE TE = 12 ms were 83% (95% CI: 36–100%) and 92% (95% CI: 80–98%), respectively.
Re-evaluation
The false negative (n = 1) and false positive (n = 4) LNs were re-evaluated. The false negative LN showed an area of 9 mm with multiple small metastatic depositions at histopathology, within an abundance of normal LN tissue with probably a normal iron uptake causing strong signal loss on MRI (Fig. 2). The first false positive LN showed homogeneous intermediate elevated signal intensity on T2*-weighted images, suggesting moderately reduced iron uptake, falsely interpreted as metastatic. The reason for this reduction was unclear. The second false positive LN remained suspect upon re-evaluation, with high signal intensity (Fig. 3). Even after thorough pathology examination, no metastases were found in these two cases. The two other false positives were caused by adjacent structures with high signal intensity being misinterpreted as LNs (small vessels and ganglions). Figures 4 and 5 show an example of a true positive and true negative LN, respectively.
Discussion
This prospective study presents a node-to-node validation of in vivo 3-T MRI with ferumoxtran-10 against histopathology for the detection of LN metastases in patients with resectable pancreatic, duodenal, or periampullary adenocarcinoma. USPIO-enhanced T2*-weighted mGRE reached a node-to-node sensitivity of 83% and specificity of 92%.
Only one previous study investigated USPIO-enhanced MRI in pancreatic cancer, using a different nanoparticle (ferumoxytol), reporting a patient-level sensitivity of 83% and specificity of 80%, based on 11 patients of which seven had PDAC. However, this study did not perform node-to-node matching and lacked clarity on the inclusion of para-aortic LNs [22]. We chose to perform node-to-node analysis with the matching of individual LNs, for detection and localisation of LN metastasis.
Our node-to-node analysis results were comparable to previous studies on LN metastase detection using USPIO-enhanced MRI in other cancer types. For instance, a sensitivity of 70% and specificity of 98% was found in node-to-node analysis for axillary LNs in 16 breast cancer patients [23]. A node-to-node study on rectal cancer demonstrated true negative rates ranging from 82% to 86% in ten patients, five of which were however partially treated with neo-adjuvant therapy [24]. A study of 77 patients with multiple cancer types found a sensitivity of 87–93% and a specificity of 73–85% [25]. Like the present study, these three studies evaluated LNs based on criteria proposed by Anzai et al [19]. A recent study in head and neck cancer introduced a novel reading algorithm, comparing LN signal intensity to lipid tissue intensity, instead of evaluating the LNs own signal pattern. Histopathologically malignant LNs showed an equal or higher signal intensity compared to lipid tissue [26]. Future research should explore the applicability of a similar strategy in pancreatic, duodenal, and periampullary cancer.
Despite our well-defined workflow [16], node-to-node correlation of in vivo MRI with histopathology was possible for only 55 LNs. This was partly due to the large number of distant LNs on MRI outside the surgical field, which could not be safely resected. Additionally, numerous small LNs directly adjacent to the pancreas, duodenum, or tumour identified at pathology, were often missed on MRI. Despite the fact that suspect LNs on MRI were shown to the surgeon preoperatively, not all distant LNs were resected, proven by their continued presence on follow-up imaging. LNs near the left renal vein were more easily identified and resected during surgery compared to those situated between the aorta and vena cava, as those are located too dorsally for safe resection. Finally, anatomical matching of LNs found on MRI within the surgical field still proved to be challenging, despite the use of ex vivo MRI, due to specimen shrinkage and altered orientation after fixation.
The majority of LNs on MRI was < 10 mm, a commonly used cut-off size for benign vs metastatic LNs [27] the majority of suspicious LNs (47/58 = 81%) on MRI was also < 10 mm. At histopathology only 20% (15/75) of LNs > 10 mm were metastatic. This suggests that LNs < 10 mm may be metastatic more frequently than commonly assumed and supports that size is not an adequate tool to detect LN metastases [11].
In our study, para-aortic LNs were the most frequently identified suspicious LNs on MRI for all tumour types, except for duodenal adenocarcinoma. Para-aortic LN metastases are regarded as distant metastases (M1) according to the TNM classification [5]. Nevertheless, the implications of distant LN metastases on treatment remains a subject of ongoing debate. This is illustrated by two meta-analyses from 2016 which included nearly identical studies but reported contradictory recommendations about resection of the primary tumour in the presence of para-aortic LN metastases [6, 7]. Extended resection of distant LNs is not recommended according to consensus reached in 2014 by the International Study Group on Pancreatic Cancer [20]. It does not improve survival and is associated with increased postoperative complications, such as chyle leakage [28,29,30]. However, studies show that adjuvant chemotherapy or chemoradiotherapy can be beneficial in patients with LN metastases in the resection specimen [31, 32]. One study showed adjuvant chemoradiotherapy has an additional survival effect compared to adjuvant chemotherapy alone, for patients with LN metastases [31]. Furthermore, in a retrospective study of patients with cN1 pancreatic cancer who received neoadjuvant chemotherapy, 38% were downstaged to ypN0 with improved survival [33]. Finally, lower rates of metastatic LNs at histopathology are reported in patients treated with neoadjuvant chemoradiotherapy compared to patients receiving immediate surgery [34]. When radiotherapy was involved, these studies used large elective radiotherapy treatment fields to cover all potentially involved LNs and to compensate for treatment uncertainties like motion, causing considerable toxicity. Given the limitations of currently used diagnostic imaging in detecting LN metastases and the uncertainty of the exact implications of the presence of LN metastases, there is still inconsistency when formulating a treatment plan. As our study shows that USPIO-enhanced MRI may be a relevant imaging technique for the detection and localisation of LN metastases, it would provide an understanding of the pattern of LN metastases and has the potential to improve therapy in patients with pancreatic, duodenal, or periampullary adenocarcinoma. Current MR-guided stereotactic body radiation therapy may play a role in this strategy by allowing the treatment of isolated LN metastases with high accuracy and limited toxicity [35]. Further studies are needed to prove this hypothesis.
Our study has several limitations. We had to exclude three patients due to unexplained inadequate uptake or distribution of USPIO contrast. Despite extensive analysis, no specific cause was identified. Therefore, for future USPIO studies, we recommend assessing the adequate contrast agent uptake in LNs first, also using sLNs in other anatomical areas for quality control. Additionally, an extensive resection of distant LNs for correlation with histopathology was not performed, because this would be unsafe due to the increased risk of complications. Finally, different measurements for LN size on MRI and pathology had to be used, making size comparison difficult. These different measurements are the result of different slicing planes on MRI and histopathology—it is technically very difficult to make them identical.
Conclusion
Concluding, in this study we performed node-to-node correlation of USPIO-enhanced MRI to histopathology in patients with pancreatic, duodenal, or peri-ampullary adenocarcinoma. The results show that USPIO-enhanced MRI is a promising technique to preoperatively detect LN metastases in patients with pancreatic, duodenal, or periampullary adenocarcinoma, with a high sensitivity and specificity. This holds promise for early detection and localisation of both local and distant LN metastases, which can be used to improve staging and guide neoadjuvant and adjuvant therapy, such as targeted radiotherapy. Further studies are needed to reveal the therapeutic potential of using USPIO-enhanced MRI for therapy guidance.
Abbreviations
- CECT:
-
Contrast-enhanced computed tomography
- EUS:
-
Endoscopic ultrasound
- 18FDG-PET-CT:
-
Fluorine-18-fluorodeoxyglucose positron emission tomography-computed tomography
- H&E:
-
Haematoxylin and eosin
- LN:
-
Lymph node
- mGRE:
-
Multi gradient echo
- MRI:
-
Magnetic resonance imaging
- OS:
-
Overall survival
- PDAC:
-
Pancreatic ductal adenocarcinoma
- UICC:
-
Union for International Cancer Control
- USPIO:
-
Ultra-small superparamagnetic iron oxide
References
Slidell MB, Chang DC, Cameron JL et al (2008) Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 15:165–174
Wellner UF, Shen Y, Keck T, Jin W, Xu Z (2017) The survival outcome and prognostic factors for distal cholangiocarcinoma following surgical resection: a meta-analysis for the 5-year survival. Surg Today 47:271–279
Meijer LL, Alberga AJ, de Bakker JK et al (2018) Outcomes and treatment options for duodenal adenocarcinoma: a systematic review and meta-analysis. Ann Surg Oncol 25:2681–2692
Lowe MC, Coban I, Adsay NV et al (2009) Important prognostic factors in adenocarcinoma of the ampulla of Vater. Am Surg 75:754–760
UICC (2016) TNM classification of malignant tumours. Wiley, New York
Paiella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C (2016) The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: a systematic review and meta-analysis. Eur J Surg Oncol 42:616–624
Agalianos C, Gouvas N, Papaparaskeva K, Dervenis C (2016) Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. HPB (Oxford) 18:633–641
Tseng DS, van Santvoort HC, Fegrachi S et al (2014) Diagnostic accuracy of CT in assessing extra-regional lymphadenopathy in pancreatic and peri-ampullary cancer: a systematic review and meta-analysis. Surg Oncol 23:229–235
Tseng DSJ, Pranger BK, van Leeuwen MS et al (2021) The role of CT in assessment of extraregional lymph node involvement in pancreatic and periampullary cancer: a diagnostic accuracy study. Radiol Imaging Cancer 3:e200014
Imai H, Doi R, Kanazawa H et al (2010) Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer. Int J Clin Oncol 15:294–300
Masuda T, Dann AM, Elliott IA et al (2018) A comprehensive assessment of accurate lymph node staging and preoperative detection in resected pancreatic cancer. J Gastrointest Surg 22:295–302
Fortuin AS, Brüggemann R, van der Linden J et al (2018) Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdiscip Rev Nanomed Nanobiotechnol 10:e1471
Scheenen TWJ, Zamecnik P (2021) The role of magnetic resonance imaging in (future) cancer staging: note the nodes. Invest Radiol 56:42–49
Harisinghani MG, Barentsz J, Hahn PF et al (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499
Wu L, Cao Y, Liao C, Huang J, Gao F (2011) Diagnostic performance of USPIO-enhanced MRI for lymph-node metastases in different body regions: a meta-analysis. Eur J Radiol 80:582–589
Driessen D, de Gouw D, Stijns RCH et al (2022) Validation of in vivo nodal assessment of solid malignancies with USPIO-enhanced MRI: a workflow protocol. Methods Protoc 5:24
Philips BWJ, Stijns RCH, Rietsch SHG et al (2019) USPIO-enhanced MRI of pelvic lymph nodes at 7-T: preliminary experience. European Radiology 29:6529–6538
JP Society (1996) Classification of pancreatic carcinoma. Kanehara, Tokyo
Anzai Y, Piccoli CW, Outwater EK et al (2003) Evaluation of neck and body metastases to nodes with ferumoxtran 10-enhanced MR imaging: phase III safety and efficacy study. Radiology 228:777–788
Tol JA, Gouma DJ, Bassi C et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156:591–600
Verbeke CS (2013) Resection margins in pancreatic cancer. Surg Clin North Am 93:647–662
McDermott S, Thayer SP, Fernandez-Del Castillo C, Mino-Kenudson M, Weissleder R, Harisinghani MG (2013) Accurate prediction of nodal status in preoperative patients with pancreatic ductal adenocarcinoma using next-gen nanoparticle. Transl Oncol 6:670–675
Nakai G, Matsuki M, Harada T et al (2011) Evaluation of axillary lymph nodes by diffusion-weighted MRI using ultrasmall superparamagnetic iron oxide in patients with breast cancer: initial clinical experience. J Magn Reson Imaging 34:557–562
Stijns RCH, Philips BWJ, Nagtegaal ID et al (2021) USPIO-enhanced MRI of lymph nodes in rectal cancer: a node-to-node comparison with histopathology. Eur J Radiol 138:109636
Harisinghani MG, Saksena MA, Hahn PF et al (2006) Ferumoxtran-10-enhanced MR lymphangiography: Does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 186:144–148
Driessen D, Zámecnik P, Dijkema T et al (2022) High-accuracy nodal staging of head and neck cancer with USPIO-enhanced MRI: a new reading algorithm based on node-to-node matched histopathology. Invest Radiol. https://doi.org/10.1097/rli.0000000000000902
Du T, Bill KA, Ford J et al (2018) The diagnosis and staging of pancreatic cancer: a comparison of endoscopic ultrasound and computed tomography with pancreas protocol. Am J Surg 215:472–475
Nimura Y, Nagino M, Takao S et al (2012) Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas: long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19:230–241
Orci LA, Meyer J, Combescure C et al (2015) A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford) 17:565–572
Shyr BU, Shyr BS, Chen SC, Shyr YM, Wang SE (2020) Chyle leakage after robotic and open pancreaticoduodenectomy. J Hepatobiliary Pancreat Sci 27:273–279
Mellon EA, Springett GM, Hoffe SE et al (2014) Adjuvant radiotherapy and lymph node dissection in pancreatic cancer treated with surgery and chemotherapy. Cancer 120:1171–1177
Merchant NB, Rymer J, Koehler EAS et al (2009) Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: Who really benefits? J Am Coll Surg 208:829–838
Tran Cao HS, Zhang Q, Sada YH et al (2017) Value of lymph node positivity in treatment planning for early stage pancreatic cancer. Surgery 162:557–567
Versteijne E, Suker M, Groothuis K et al (2020) Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial. J Clin Oncol 38:1763–1773
Henke L, Kashani R, Robinson C et al (2018) Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol 126:519–526
Acknowledgements
We thank the pathology technicians (Ingrid Pater-van den Heuvel, Ilse de Laak-de Vries, and Floor Vos) and MRI technicians (Andor Veltien and Sjaak van Asten) for their efforts in making this study possible. We thank the private funder that made this study possible.
Funding
This study has received funding from a private anonymous funder. The funder had no role in the design of the study, in the collection, analyses, or interpretation of the data, in the writing of the manuscript or in the decision where to publish the results.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is John J Hermans.
Conflict of Interest
The authors of this manuscript declare relationships with the following companies: Patrik Zámecnik declares to be a “Scientific Advisor to SPL Medical B.V.” and owner of shares of SPL Medical B.V. The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Informed consent
Written informed consent was obtained from all subjects (patients) in this study.
Ethical approval
Institutional Review Board approval was obtained from the Medical Research Ethics Committee Oost-Nederland.
Study subjects or cohorts overlap
No study subjects or cohorts have been previously reported.
Methodology
-
Prospective
-
Diagnostic or prognostic study
-
Performed at one institution
Additional information
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Litjens, G., Nakamoto, A., Brosens, L.A.A. et al. Ferumoxtran-10-enhanced MRI for pre-operative metastatic lymph node detection in pancreatic, duodenal, or periampullary adenocarcinoma. Eur Radiol (2024). https://doi.org/10.1007/s00330-024-10838-w
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00330-024-10838-w